Drug updated on 3/28/2024
| Dosage Form | Injection (subcutaneous; 225 mg/1.5 mL) |
| Drug Class | Calcitonin gene-related peptide receptor antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the preventive treatment of migraine in adults.
Summary
- Fremanezumab (Ajovy) is indicated for the preventive treatment of migraine in adults.
- A total of 15 systematic reviews/meta-analyses were reviewed to gather information about this drug.
- When compared with other Calcitonin Gene-Related Peptide (CGRP) monoclonal antibodies such as erenumab, galcanezumab, and eptinezumab, fremanezumab (Ajovy) demonstrated comparable or superior efficacy in reducing monthly migraine days after six weeks among chronic and episodic patients.
- Compared to traditional preventatives like onabotulinumtoxinA or topiramate, fremanezumab (Ajovy), along with other CGRP monoclonal antibodies showed a better safety profile and higher likelihood-to-help-versus-harm ratio making it a more favorable option for those suffering from migraines.
- In terms of adverse events, fremanezumab's rate was similar to that of placebo groups across studies; certain doses had slightly higher rates but overall the safety profiles were excellent according to these documents.
- The risk associated with serious adverse events related to treatment using CGRP monoclonal antibodies including fremanezumanb was found similar when compared against placebos indicating their safe use over long periods based on these studys reviewed.
- For resistant chronic migraine cases where standard therapies have low adherence due to weak safety profiles, Ajovy has been highlighted as potentially effective alongside other CGRP antagonists.
- Data suggests that patients suffering from episodic migraines might benefit more from monthly administration while both quarterly and monthly administrations are effective for those having chronic migraines suggesting personalization based on subtype could be beneficial according these document analyses done here.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Ajovy (Fremanezumab-vfrm) Prescribing Information. | 2022 | Teva Pharmaceuticals USA, North Wales, PA |
Systematic Reviews / Meta-Analyses
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| European Headache Federation guideline on the use of monoclonal antibodies targeting the calcitonin gene related peptide pathway for migraine prevention - 2022 update. | 2022 | The Journal of Headache and Pain |
| The primary care management of headache: synopsis of the 2020 U.S. department of veterans affairs and U.S. department of defense clinical practice guideline. | 2022 | Military Medicine |